Beta-2 subunit-containing nicotinic acetylcholine receptor (β2*-nAChR) (β2*-nAChR)

Beta-2 subunit-containing nicotinic acetylcholine receptors (β2*-nAChRs) are pentameric ligand-gated ion channels that represent the most abundant high-affinity nicotinic receptor class in the mammalian brain (Gotti et al., 2006, PMID: 17030501). These receptors are primarily composed of α4 and β2 subunits, though they can incorporate other subunits like α6 or β3, which are designated by the asterisk notation. They function by facilitating the influx of cations such as sodium and calcium upon binding to acetylcholine or exogenous agonists like nicotine, thereby modulating the release of various neurotransmitters, including dopamine, GABA, and glutamate (Albuquerque et al., 2009, PMID: 19126755). Due to their high density in the mesolimbic dopaminergic pathway, β2*-nAChRs are the principal mediators of the reinforcing effects of nicotine and are the primary targets for smoking cessation therapies (StatPearls, NBK531461). Mutations in the CHRNB2 gene, which encodes the β2 subunit, are linked to Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (ADNFLE), highlighting their role in maintaining excitatory-inhibitory balance (De Fusco et al., 2000, PMID: 10932192). Furthermore, the loss of these receptors is a hallmark of neurodegenerative diseases such as Alzheimer's and Parkinson's, making them significant targets for cognitive enhancement and neuroprotection (Picciotto & Zoli, 2008, PMID: 18297041). Pharmacological agents targeting these receptors include partial agonists like varenicline, which provide relief from withdrawal symptoms while antagonizing the effects of continued nicotine use. Therapeutic development also explores positive allosteric modulators to enhance cholinergic signaling in cognitive disorders.

Other names

β2-containing nAChRBeta-2 nicotinic acetylcholine receptorCHRNB2-containing receptorHigh-affinity nicotinic receptorα4β2 nicotinic acetylcholine receptor

Agonist, partial agonist, or antagonist activity at the orthosteric binding site, or allosteric modulation, leading to the opening or closing of the integral cation channel (Albuquerque et al., 2009, PMID: 19126755).